Efficacy and safety associated with immune checkpoint inhibitors in unresectable hepatocellular carcinoma: A re-analysis of a meta-analysis

被引：0

作者：

Zhou, Shouhao ^{[1
,2
,4
]}

Shen, Chan ^{[1
,2
,3
]}

机构：

[1] Penn State Univ, Coll Med, Dept Publ Hlth Sci, Hershey, PA 17033 USA

[2] Penn State Univ, Penn State Canc Inst, Hershey, PA 17033 USA

[3] Penn State Univ, Coll Med, Dept Surg, Hershey, PA 17033 USA

[4] Penn State Univ, Dept Publ Hlth Sci, 90 Hope Dr,ASB 3400L, Hershey, PA 17033 USA

来源：

JGH OPEN | 2023年 / 7卷 / 02期

关键词：

Bayesian statistics; immune checkpoint inhibitors; meta-analysis; predictive intervals; unresectable hepatocellular carcinoma;

D O I：

10.1002/jgh3.12856

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

We identified analytic limitations in a recent meta-analysis and re-examined the efficacy and safety associated with immune checkpoint inhibitors (ICIs) in unresectable hepatocellular carcinoma (HCC) compared with standard therapies. Our findings mostly contradict conclusions from the previous study, suggesting the need for continuing the investigation of ICIs in HCC with additional clinical evidence.

引用

页码：163 / 164

页数：2

共 50 条

[31] Comparative efficacy and safety of transarterial chemoembolization combined with tyrosine kinase inhibitors and immune checkpoint inhibitors versus tyrosine kinase inhibitors and immune checkpoint inhibitors alone in advanced hepatocellular carcinoma: a systematic review and meta-analysis
Hengyu Tian
Chidan Wan
World Journal of Surgical Oncology, 23 (1)
[32] Safety of immune checkpoint inhibitors: An updated comprehensive disproportionality analysis and meta-analysis
Tyagi, Simran
Kumar, Anoop
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2024, 200
[33] Safety, efficacy, and tolerability of immune checkpoint inhibitors in the treatment of hepatocellular carcinoma
Brown, Zachary J.
Gregory, Stephanie
Hewitt, D. Brock
Iacono, Stephen
Choe, Jennie
Labiner, Hanna E.
Pawlik, Timothy M.
SURGICAL ONCOLOGY-OXFORD, 2022, 42
[34] Safety and efficacy of immune checkpoint inhibitors in advanced cancer patients with autoimmune disease: A meta-analysis
Cai, Qi
Huo, Geng-wei
Zhu, Fu-yi
Yue, Ping
Yuan, Dong-qi
Chen, Peng
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2022,
[35] The clinical value of combination of immune checkpoint inhibitors in cancer patients: A meta-analysis of efficacy and safety
Wu, Yingcheng
Shi, Hui
Jiang, Maorong
Qiu, Mingyan
Jia, Keren
Cao, Tianyue
Shang, Yujuan
Shi, Lili
Jiang, Kui
Wu, Huiqun
INTERNATIONAL JOURNAL OF CANCER, 2017, 141 (12) : 2562 - 2570
[36] Efficacy and safety of immune checkpoint inhibitors for patients with prostate cancer: a systematic review and meta-analysis
Noori, Maryam
Azizi, Shadi
Mahjoubfar, Aref
Varaki, Farhan Abbasi
Fayyaz, Farimah
Mousavian, Amir-Hossein
Bashash, Davood
Parizi, Mehdi Kardoust
Kasaeian, Amir
FRONTIERS IN IMMUNOLOGY, 2023, 14
[37] Correlation between surrogate endpoints and overall survival in unresectable hepatocellular carcinoma patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
Litao Huang
Deying Kang
Chongyang Zhao
Xueting Liu
Scientific Reports, 14
[38] Correlation between surrogate endpoints and overall survival in unresectable hepatocellular carcinoma patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
Huang, Litao
Kang, Deying
Zhao, Chongyang
Liu, Xueting
SCIENTIFIC REPORTS, 2024, 14 (01)
[39] Efficacy and Safety of Immune Checkpoint Inhibitor in Advanced Esophageal Squamous Cell Carcinoma: A Meta-Analysis
Gu, Yi-Min
Shang, Qi-Xin
Zhuo, Yue
Zhou, Jian-Feng
Liu, Bo-Wei
Wang, Wen-Ping
Che, Guo-Wei
Chen, Long-Qi
FRONTIERS IN ONCOLOGY, 2021, 11
[40] Approved immune checkpoint inhibitors in hepatocellular carcinoma: a large-scale meta-analysis and systematic review
Zhang, Ruyi
Wang, Fang
You, Zhiyu
Deng, Dongyang
He, Jiangyan
Yan, Wentao
Quan, Jian
Wang, Jing
Yan, Shujuan
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2024, 150 (02)

← 1 2 3 4 5 →